Brain-computer interface enables thought-controlled walking after spinal cord injury
"This publication shows that the significant potential of ARC therapy can be extended by the introduction of a BCI, allowing more natural movements based on a paralyzed person's thoughts," said Dave Marver, CEO of ONWARD. "With our superior understanding of spinal cord stimulation for people with SCI, we have positioned ONWARD as a leader in BCI."
"BCI provides a continuous link between movement intentions and spinal cord stimulation, enabling a more natural recovery of mobility," said neuroscientist Grégoire Courtine, professor at EPFL and co-author of the Nature article. "I look forward to advancing this important new technology with the ONWARD team."
The data released are part of an ongoing clinical feasibility study investigating the safety and preliminary efficacy of brain-guided spinal cord stimulation after SCI. The study is being coordinated by .NeuroRestore co-directors - Grégoire Courtine and Jocelyne Bloch, neurosurgeon at the University Hospital of Lausanne (CHUV) - and Guillaume Charvet, head of the medical device development laboratory at CEA-Leti / Clinatec.
All ONWARD devices and therapies, including but not limited to ARC-IM, ARC-EX and ARC Therapy, are in the trial phase and are not available for commercial use.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.